Sollis Therapeutics

In April 2018, Deerfield invested in Sollis Therapeutics. Sollis is developing a drug / device combination consisting of Polylactic acid + Clonidine for the treatment of sciatica. Current treatment options consist of opioids, NSAIDs, and epidural injections, each of which have minimal therapeutic benefit. The PLA + Clonidine combination results in controlled bioresorbability and distribution over a 52 week period, creating a longer term benefit.